Tuesday, January 31, 2012
Wilmington, N.C.-based CRO Pharmaceutical Product Development (PPD) and Rochester, N.Y.-based VirtualScopics have expanded their one-year strategic alliance in clinical and medical imaging services across multiple therapeutic areas to now include oncology, central nervous system, cardiovascular, general medicine and medical devices.
Transparency Life Sciences (TLS), the first drug development company based on open innovation, has officially launched, with the introduction of a prototype of its crowdsourced web platform that allows patients, physicians, researchers and other stakeholders to contribute to the design of clinical studies.
Patheon, a global provider of drug development and manufacturing services, has promoted Antonella Mancuso to president, global commercial operations and chief manufacturing officer, responsible for Patheon’s global commercial manufacturing operations. Mancuso will assume responsibility for all of Patheon’s commercial operating units in North America and Europe.
Bernard Tyson, president and COO of Kaiser Permanente, has been named chair of the Executive Leadership Council (ELC)—a preeminent organization composed of African-American senior executives from the nation’s Fortune 500 corporations that recognizes the strengths, success, contributions and impact of African-American business leaders. His term runs through Dec. 31, 2013.
Genentech’s Erivedge (vismodegib) has been approved by the FDA to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).
Circadian Technologies has published data in Investigative Ophthalmology & Visual Science (IOVS) showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. The data also showed that VEGF-C blockade, through administration of Circadian’s lead development candidate VGX-100, a human antibody against VEGF-C, significantly improved corneal graft survival in an animal model. The data indicates a new therapeutic opportunity for VGX-100 to improve corneal graft survival.